Trevi Therapeutics Announced That Data From The Phase 2A Canal Trial Will Be Presented At CHEST 2024, Including An Analysis Of Cough Relief In Patients With Idiopathic Pulmonary Fibrosis Who Were Treated With Nalbuphine ER
Portfolio Pulse from Benzinga Newsdesk
Trevi Therapeutics will present data from its Phase 2A Canal Trial at CHEST 2024, focusing on cough relief in idiopathic pulmonary fibrosis patients treated with Nalbuphine ER.
September 26, 2024 | 11:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Trevi Therapeutics is set to present promising data from its Phase 2A Canal Trial at CHEST 2024, which could positively impact its stock price due to potential advancements in treating idiopathic pulmonary fibrosis with Nalbuphine ER.
The announcement of presenting trial data at a major conference like CHEST 2024 suggests potential positive developments in Trevi's treatment for idiopathic pulmonary fibrosis. This could lead to increased investor interest and a positive short-term impact on TRVI's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100